NEW YORK, NY / ACCESSWIRE / February 17, 2016 / Pomerantz LLP is investigating claims on behalf of investors of Catalyst Pharmaceuticals, Inc. ("Catalyst" or the "Company") (NASDAQ: CPRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Catalyst and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On February 17, 2016, pre-market, Catalyst announced that the Company has received a "Refusal To File" letter from the U.S. Food and Drug Administration regarding its New Drug Application for Firdapse (amifampridine phosphate). The "Refusal to File" letter states that after a preliminary review, the FDA has found that the application, which was submitted in December 2015, was not sufficiently complete, and requests additional supporting information. The letter does not provide comment on the acceptability of the submitted clinical data, and no judgment is made in the letter on the efficacy or safety of Firdapse.

On this news, Catalyst stock has fallen as much as $0.92 per share, or nearly 50%, to $0.93 per share during intraday trading on February 17, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP